- Home
- NMRK vs IDYA Comparison
NMRK vs IDYA Comparison
Compare NMRK & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRK | IDYA |
|---|---|---|
| Founded | 1929 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.9B |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NMRK | IDYA |
|---|---|---|
| Price | $17.39 | $34.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $19.60 | ★ $49.67 |
| AVG Volume (30 Days) | 920.2K | ★ 934.6K |
| Earning Date | 02-25-2026 | 02-17-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ 94.50 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $3,160,782,000.00 | $214,834,000.00 |
| Revenue This Year | $22.26 | $2,688.43 |
| Revenue Next Year | $9.89 | N/A |
| P/E Ratio | $30.26 | ★ N/A |
| Revenue Growth | 20.95 | ★ 5377.66 |
| 52 Week Low | $9.65 | $13.45 |
| 52 Week High | $19.84 | $39.28 |
Technical Indicators
Market Signals| Indicator | NMRK | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 46.52 |
| Support Level | $17.15 | $31.62 |
| Resistance Level | $18.25 | $35.38 |
| Average True Range (ATR) | 0.62 | 1.55 |
| MACD | 0.02 | -0.41 |
| Stochastic Oscillator | 49.73 | 38.13 |
Price Performance
Historical ComparisonAbout NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.